Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LungLife AI, Inc. ( (GB:LLAI) ) has issued an update.
LungLife AI, Inc. has appointed Allenby Capital Limited as its new Nominated Adviser and Joint Broker, alongside existing broker Goodbody, to enhance its corporate advisory and brokering capabilities. This strategic move is part of LungLife’s efforts to strengthen its market positioning and operational effectiveness in the competitive landscape of lung cancer diagnostics.
More about LungLife AI, Inc.
LungLife AI, Inc. operates in the healthcare industry, focusing on the development of clinical diagnostic solutions for lung cancer. The company offers the LungLB® test, which uses a minimally invasive blood draw to aid clinicians in evaluating indeterminate lung nodules, with a mission to improve early detection rates of lung cancer.
YTD Price Performance: -76.47%
Average Trading Volume: 275,900
Technical Sentiment Consensus Rating: Buy
For a thorough assessment of LLAI stock, go to TipRanks’ Stock Analysis page.